Table 3.
Univariate and multivariate analysis for clinical outcome, microbiological outcome and mortality in patients treated with tigecycline inside vs. outside the critical care area.
| Variables | Total (N = 153) | Univariate model | Adjusted multivariate model* | |||
|---|---|---|---|---|---|---|
| Critically ill patients (n = 47) | Patients outside critical care area (n = 106) | P | Odds ratio (95 % confidence interval) | P | ||
| Clinical | ||||||
| Outcome | ||||||
| Success | 59 (43.4%) | 14 (31.1%) | 45 (49.5%) | 0.04 | 1.07 (0.45–2.57) | 0.87 |
| Failure | 77 (56.6%) | 31 (68.9%) | 46 (50.5%) | |||
| Microbiological | ||||||
| Outcome | ||||||
| Success | 26 (43.3%) | 8 (36.4%) | 18 (47.4%) | 0.41 | 0.96 (0.29–3.26) | 0.95 |
| Failure | 34 (56.7%) | 14 (63.6%) | 20 (52.6%) | |||
| Total mortality | 69 (45.1%) | 25 (53.2%) | 44 (41.5%) | 0.18 | 0.82 (0.36–1.89) | 0.65 |
| 7 days post-treatment mortality | 51 (33.3%) | 20 (42.6%) | 31 (29.2%) | 0.11 | 1.15 (0.52–2.54) | 0.73 |
| In-hospital mortality | 18 (11.8%) | 5 (10.6%) | 13 (12.3%) | 0.77 | 0.85 (0.28–2.54) | 0.77 |
Potentially confounding variables controlled for in the adjusted model
were: cardiovascular disease, vasopressors given before or ≤ 24 h of tigecycline therapy, mechanical ventilation, neutropenia (<500 mm3), ventilator associated pneumonia, treatment strategy; combination therapy using tigecycline plus aminoglycoside.
N.B. Calculation of clinical and microbiological success and failure rates for all categories is done as such:
1-Clinical success rate (%) = Number of patients with clinical success/(Number of patients with clinical success + Number of patients with clinical failure) × 100.
2-Microbiological success rate (%) = Number of patients with microbiological success/(Number of patients with microbiological success + Number of patients with microbiological failure) × 100.